By Fineline Cube 
China-based Qure Biotechnology (Shanghai) Co., Ltd. announced the completion of a Series C1 financing round totaling RMB 100 million (USD 14 million), led by Efung Capital. This milestone supports the company’s ongoing development of innovative biologic drugs targeting challenging cancers, autoimmune disorders, and inflammatory diseases.
Company Focus and Technology
QureBio specializes in the development of bispecific and multispecific antibodies and protein-based therapeutics. Utilizing protein engineering and proprietary technologies, the company has established a robust pipeline of in-house developed products.
Pipeline Progress
Q-1802, a Claudin18.2/PD-L1 bispecific antibody, has completed Phase II patient enrollment and is preparing for Phase III trials. Meanwhile, Q-1801, an SIRP⍺/PD-L1 bispecific antibody, has received clinical trial approvals in both China and the U.S., with studies set to commence shortly.-Fineline Info & Tech